| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Outline of Final Research Achievements |
Non-curable tumors, including pancreatic cancer and musculoskeletal tumors, remains clinically challenging, and requires the identification of new molecular target that can be therapeutically exploited to improve patient outcome. Here, our studies demonstrate that a candidate molecule shapes the refractory tumor microenvironment through stratified experimental approaches, i.e. clinical patient data, pathological analysis, cell-molecular-genome analysis, bioinformatics, compound screening, and mouse models. The results highlight a drug suggesting a potential therapeutic strategy, “Normalization of tumor microenviroment” for mitigating refractory tumors. Thus, our new outlook suggests delivering a novel treatments, providing a hope to patients afflicted with non-curable tumors.
|
